ONL Therapeutics

IN THE PRESS

BioMidwest

ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research

January 26, 2023

·

2 min read

Drug Development

AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study

July 12, 2022

·

3 min read

Business

ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer

February 9, 2022

·

4 min read

BioMidwest

ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones

January 13, 2022

·

3 min read

Business

ONL Therapeutics Names Connie Chang as Chief Operating OfficerCompany expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration

January 19, 2021

·

3 min read

BioMidwest

ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications

December 22, 2020

·

4 min read

BioMidwest

ONL Therapeutics Announces First Patient Treated in Phase I Study with ONL1204ONL Therapeutics transformed into a clinical stage biopharmaceutical company with first-in-human study

October 23, 2019

·

3 min read

BioMidwest

ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases

May 18, 2017

·

3 min read

Business

ONL Therapeutics Strengthens Leadership With Addition To Board Of Directors And Expansion Of Operations Team

March 29, 2017

·

6 min read

BioMidwest

ONL Therapeutics Receives Nearly $1.0 Million Grant From National Eye Institute For Continued Advancement Of ONL1204 Program

March 21, 2017

·

3 min read

JOBS